{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000078","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.745216+00:00","generated_at":"2026-05-17T21:30:09.906757+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue","bullets":["VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.","Net income $38.3M vs $15.6M YoY; basic EPS $1.33, diluted EPS $1.29.","Cash and investments $820.8M; FY 2025 non-GAAP R&D+SG&A guidance $150-175M.","VYJUVEK approved in Japan for DEB patients from birth; launch expected by end of 2025.","First patient dosed in Phase 3 IOLITE study (KB803 for corneal abrasions in DEB) and Phase 2 EMERALD-1 (KB801 for NK)."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000078","json":"https://secwatch.observer/filing/0001711279-25-000078.json","markdown":"https://secwatch.observer/filing/0001711279-25-000078.md","text":"https://secwatch.observer/filing/0001711279-25-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/0001711279-25-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/krys-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:30:09.906757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}